ESLT just delivered its sharpest single-day gain in months — a 9.5% surge to ILS 2,420 on Tuesday, capping a 7.1% week — and the catalysts are stacking up fast.
Q1 earnings landed on May 26 alongside a $1.4 billion European military modernisation contract, the kind of combination that forces even hesitant holders off the sidelines. The company also announced the acquisition of Bluewhite, an AI autonomous-vehicle developer, through its FUSE subsidiary, deepening its push into multi-domain robotics. The backlog has passed $30 billion. JP Morgan responded the same day, maintaining its Neutral rating but raising its price target to $950 — a meaningful signal that even cautious Street voices are marking up their numbers in response to the order flow.
Borrow conditions for ESLT are effectively non-existent as a pressure point. Short interest is a token 0.24% of the free float — down from around 0.32% in late April, as the prior bears who had crept in have been steadily unwinding throughout May. Availability sits at 2,823% of short interest, meaning roughly 28 shares are available to borrow for every one currently lent out. The borrow market is loose by any standard. Cost to borrow has drifted up 39% on the week to 0.57%, but that remains firmly in low single digits — there is no squeeze dynamic, no forced-cover pressure. The ORTEX short score of 26.7 sits in the low end of the range, consistent with a stock where bears have largely stepped aside.
The Street has been slow to reprice what has been a genuine re-rating story. The JP Morgan $950 target published today looks notably light against Tuesday's close of ILS 2,420 — the two figures are almost certainly referencing different share classes or listing venues (ESLT trades in ILS on the Tel Aviv Stock Exchange), so that precise target number should be treated with caution. What is clear is the directional message: a traditionally cautious house is lifting numbers into strength. The ORTEX stock score sits at 82, with Momentum at 76.5 and Quality at 74.5 driven by an F-Score of 8. The weak link remains Value — a P/E near 55x and price-to-book of 7.1x mean that fresh buyers are paying up, and the EV/EBITDA multiple of 12.1x has edged higher over the past month as the stock has outpaced earnings growth.
The most interesting ownership footnote this week is that April 9 insider activity — the last reported date — showed the President/CEO and multiple EVPs selling roughly $22.6 million and $23.9 million worth of stock respectively, all at prices around ILS 887–898. Those exits look well-timed in retrospect: the stock has rallied roughly 170% from those levels in under two months, meaning the insider sells were transactional rather than a read on the business. The 90-day net share figure of +82,000 shares suggests those sales were largely offset by option awards or other acquisitions elsewhere in the window. Federmann Enterprises, the founding family vehicle, still holds 41.3% of shares outstanding and trimmed only modestly (261,834 shares) in Q1. Vanguard Capital Management and Phoenix Investments both reported fresh positions in the quarter, while Mirae Asset added 118,000 shares.
Peers offer a useful cross-check on whether Tuesday's move was idiosyncratic or sector-driven. BSEN on TASE gained 6.8% on the day and 18.1% on the week — a stronger move than ESLT itself. SAAB B added 12% on the week and RHM advanced 10.5%, suggesting a broad European defence re-rating is underway rather than a purely ESLT-specific story. By contrast, KRMN gave up 5.4% on the day, a reminder that US defence names are not moving in lockstep with the European and Israeli names that have direct exposure to ongoing procurement.
The next scheduled earnings event is not yet confirmed, so attention shifts to whether the $1.4 billion European contract generates further follow-on announcements and whether management clarifies the Bluewhite acquisition terms on any forthcoming investor calls.
See the live data behind this article on ORTEX.
Open ESLT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
